Jasper Therapeutics (JSPR)
Jasper Therapeutics on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq.
6.2M
Short interest
settlement 2026-09-30
16.3
Days to cover
-0.1 days vs prior
39.3%
Short share of volume
2026-10-23
94,235
Fails to deliver
settlement 2026-09-30
Mon 9 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-10-23.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in JSPR is 6,218,239 shares, up 726,122 shares over the last month. Over the last 48 readings it ranged from 1,120,087 shares (29 August 2025) to 6,218,239 shares (30 September 2026). The latest reading sits at the top of that range. At the reported average volume of 382K shares a day that is 16.3 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/jspr" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 6,218,239 | +7.1% | 381,578 | 16.30 |
| 2026-09-15 | 5,808,274 | +5.8% | 353,411 | 16.43 |
| 2026-08-31 | 5,492,117 | +2.5% | 714,460 | 7.69 |
| 2026-08-14 | 5,358,334 | +24.3% | 690,501 | 7.76 |
| 2026-07-31 | 4,311,877 | +159.5% | 4,576,589 | 1.00 |
| 2026-07-15 | 1,661,803 | -2.4% | 882,127 | 1.88 |
| 2026-06-30 | 1,703,161 | -13.0% | 623,080 | 2.73 |
| 2026-06-15 | 1,958,290 | -12.8% | 957,316 | 2.05 |
| 2026-05-29 | 2,246,874 | -9.7% | 236,234 | 9.51 |
| 2026-05-15 | 2,487,193 | -8.5% | 242,615 | 10.25 |
| 2026-04-30 | 2,719,374 | -0.4% | 352,892 | 7.71 |
| 2026-04-15 | 2,730,146 | -9.4% | 819,157 | 3.33 |
| 2026-03-31 | 3,015,156 | -3.4% | 357,201 | 8.44 |
| 2026-03-13 | 3,120,042 | -6.6% | 416,643 | 7.49 |
| 2026-02-27 | 3,340,380 | -2.7% | 265,624 | 12.58 |
| 2026-02-13 | 3,433,577 | -3.5% | 567,107 | 6.05 |
| 2026-01-30 | 3,559,637 | -2.3% | 502,572 | 7.08 |
| 2026-01-15 | 3,643,903 | +13.0% | 1,453,886 | 2.51 |
| 2025-12-31 | 3,224,369 | -6.7% | 706,758 | 4.56 |
| 2025-12-15 | 3,455,246 | +88.6% | 6,402,040 | 1.00 |
| 2025-11-28 | 1,831,825 | +21.4% | 371,443 | 4.93 |
| 2025-11-14 | 1,508,904 | -1.1% | 447,904 | 3.37 |
| 2025-10-31 | 1,525,711 | -1.4% | 372,754 | 4.09 |
| 2025-10-15 | 1,547,641 | +2.4% | 431,572 | 3.59 |
| 2025-09-30 | 1,511,116 | +30.1% | 510,910 | 2.96 |
| 2025-09-15 | 1,161,897 | +3.7% | 161,211 | 7.21 |
| 2025-08-29 | 1,120,087 | -8.6% | 144,096 | 7.77 |
| 2025-08-15 | 1,226,019 | -4.9% | 284,301 | 4.31 |
| 2025-07-31 | 1,288,779 | -4.9% | 335,364 | 3.84 |
| 2025-07-15 | 1,355,502 | +5.2% | 2,437,005 | 1.00 |
| 2025-06-30 | 1,289,117 | -16.4% | 471,021 | 2.74 |
| 2025-06-13 | 1,542,695 | -10.6% | 242,057 | 6.37 |
| 2025-05-30 | 1,726,438 | -1.0% | 217,129 | 7.95 |
| 2025-05-15 | 1,744,284 | +0.9% | 158,382 | 11.01 |
| 2025-04-30 | 1,729,447 | -3.3% | 156,644 | 11.04 |
| 2025-04-15 | 1,787,909 | -4.4% | 187,707 | 9.52 |
| 2025-03-31 | 1,870,350 | +12.1% | 202,052 | 9.26 |
| 2025-03-14 | 1,668,204 | -19.6% | 310,230 | 5.38 |
| 2025-02-28 | 2,076,215 | -17.0% | 360,163 | 5.76 |
| 2025-02-14 | 2,500,941 | -8.0% | 424,309 | 5.89 |
| 2025-01-31 | 2,718,649 | -15.4% | 546,135 | 4.98 |
| 2025-01-15 | 3,215,172 | +38.8% | 1,558,468 | 2.06 |
| 2024-12-31 | 2,317,294 | +11.8% | 208,848 | 11.10 |
| 2024-12-13 | 2,073,310 | +0.9% | 174,706 | 11.87 |
| 2024-11-29 | 2,055,404 | +6.0% | 177,687 | 11.57 |
| 2024-11-15 | 1,938,630 | +10.4% | 241,908 | 8.01 |
| 2024-10-31 | 1,755,785 | -3.0% | 358,301 | 4.90 |
| 2024-10-15 | 1,809,935 | +21.1% | 359,347 | 5.04 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 23 October 2026, the short share of JSPR volume is 39.3%, down 17.1 points over the last five sessions. Over the last 30 readings it ranged from 22.0% (15 September 2026) to 91.1% (9 October 2026). The latest reading is 21.4 points below the 30-session average of 60.7%, on 91K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-23 | 36K | 91K | 39.3% | 100 |
| 2026-10-22 | 20K | 25K | 77.2% | 0 |
| 2026-10-21 | 101K | 157K | 64.3% | 0 |
| 2026-10-20 | 102K | 135K | 75.6% | 0 |
| 2026-10-19 | 64K | 167K | 38.1% | 1,076 |
| 2026-10-16 | 49K | 87K | 56.4% | 700 |
| 2026-10-15 | 124K | 156K | 79.9% | 209 |
| 2026-10-14 | 179K | 301K | 59.5% | 14,957 |
| 2026-10-13 | 84K | 126K | 66.7% | 5,164 |
| 2026-10-12 | 118K | 133K | 88.6% | 1 |
| 2026-10-09 | 97K | 106K | 91.1% | 2,261 |
| 2026-10-08 | 47K | 65K | 72.3% | 201 |
| 2026-10-07 | 124K | 162K | 76.7% | 363 |
| 2026-10-06 | 71K | 117K | 60.8% | 217 |
| 2026-10-05 | 191K | 227K | 84.4% | 206 |
| 2026-10-02 | 42K | 73K | 57.6% | 206 |
| 2026-10-01 | 55K | 105K | 52.0% | 0 |
| 2026-09-30 | 155K | 208K | 74.6% | 0 |
| 2026-09-29 | 180K | 258K | 69.9% | 0 |
| 2026-09-28 | 50K | 131K | 37.9% | 1 |
| 2026-09-25 | 25K | 70K | 36.1% | 100 |
| 2026-09-24 | 87K | 158K | 55.4% | 659 |
| 2026-09-23 | 175K | 214K | 81.8% | 100 |
| 2026-09-22 | 52K | 94K | 55.6% | 0 |
| 2026-09-21 | 38K | 116K | 33.1% | 0 |
| 2026-09-18 | 46K | 71K | 65.4% | 0 |
| 2026-09-17 | 139K | 171K | 81.0% | 1,063 |
| 2026-09-16 | 57K | 227K | 25.3% | 8,844 |
| 2026-09-15 | 46K | 209K | 22.0% | 764 |
| 2026-09-14 | 76K | 179K | 42.5% | 31 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 30 September 2026, the fails-to-deliver balance in JSPR is 94,235 shares, up 85,467 shares over the last settlement date. Over the last 30 readings it ranged from 324 shares (22 September 2026) to 757,214 shares (17 July 2026).
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-30 | 94,235 | $0.63 | $59K |
| 2026-09-29 | 8,768 | $0.63 | $6K |
| 2026-09-28 | 17,299 | $0.61 | $11K |
| 2026-09-25 | 29,693 | $0.59 | $18K |
| 2026-09-24 | 24,303 | $0.57 | $14K |
| 2026-09-22 | 324 | $0.60 | $194 |
| 2026-09-21 | 9,913 | $0.62 | $6K |
| 2026-09-18 | 28,790 | $0.63 | $18K |
| 2026-09-17 | 10,097 | $0.58 | $6K |
| 2026-09-08 | 6,920 | $0.71 | $5K |
| 2026-08-28 | 5,735 | $0.70 | $4K |
| 2026-08-26 | 333 | $0.72 | $240 |
| 2026-08-20 | 8,988 | $0.75 | $7K |
| 2026-08-18 | 35,631 | $0.84 | $30K |
| 2026-08-17 | 52,878 | $0.79 | $42K |
| 2026-08-14 | 38,041 | $0.86 | $33K |
| 2026-08-13 | 56,167 | $0.82 | $46K |
| 2026-08-12 | 19,284 | $0.89 | $17K |
| 2026-08-11 | 6,196 | $0.80 | $5K |
| 2026-08-10 | 171,222 | $0.71 | $122K |
| 2026-08-07 | 1,097 | $0.65 | $713 |
| 2026-08-06 | 46,715 | $0.66 | $31K |
| 2026-08-05 | 52,406 | $0.67 | $35K |
| 2026-07-23 | 15,201 | $0.74 | $11K |
| 2026-07-21 | 14,699 | $0.81 | $12K |
| 2026-07-20 | 28,605 | $0.89 | $25K |
| 2026-07-17 | 757,214 | $0.77 | $583K |
| 2026-07-01 | 8,036 | $0.42 | $3K |
| 2026-06-30 | 3,462 | $0.42 | $1K |
| 2026-06-29 | 80,013 | $0.34 | $27K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for JSPR in the last 90 days. The most recent filings are listed below. Latest filing: WIGGANS THOMAS G (Director) on 2025-09-22.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2025-09-22 | WIGGANS THOMAS G | Director | Buy | 41K | $2.43 | $100K | 41K |
| 2025-09-22 | Lucas Svetlana | Director | Buy | 20K | $2.43 | $49K | 20K |
| 2025-09-22 | MARTELL RON | President and CEO | Buy | 41K | $2.43 | $100K | 74K |
| 2025-09-22 | Shizuru Judith Anne | Director | Buy | 41K | $2.43 | $100K | 157K |
| 2024-12-12 | Mahal Jeetinder Singh | Chief Operating Officer | Sell | 900 | $22.11 | $20K | 25K |
| 2024-12-12 | Mahal Jeetinder Singh | Chief Operating Officer | Exercise or conversion | 900 | $7.10 | $6K | 26K |
| 2024-09-12 | Mahal Jeetinder Singh | Chief Operating Officer | Exercise or conversion | 900 | $7.10 | $6K | 26K |
| 2024-09-12 | Mahal Jeetinder Singh | Chief Operating Officer | Sell | 900 | $21.23 | $19K | 25K |
| 2024-06-12 | Mahal Jeetinder Singh | Chief Operating Officer | Exercise or conversion | 900 | $7.10 | $6K | 26K |
| 2024-06-12 | Mahal Jeetinder Singh | Chief Operating Officer | Sell | 900 | $24.16 | $22K | 25K |
| 2024-06-07 | Tucker Edwin Jonathan | Chief Medical Officer | Grant | 400 | $4.17 | $2K | 400 |
| 2024-03-12 | Mahal Jeetinder Singh | Chief Operating Officer | Exercise or conversion | 900 | $7.10 | $6K | 26K |
| 2024-03-12 | Mahal Jeetinder Singh | Chief Operating Officer | Sell | 900 | $26.44 | $24K | 25K |
| 2024-02-08 | VENKATARAMAN BALAJI | TenPercentOwner | Buy | 350K | $12.95 | $4.5M | 1.2M |
| 2024-02-08 | Abingworth LLP | TenPercentOwner | Buy | 190K | $12.95 | $2.5M | 1.1M |
| 2023-11-28 | WIGGANS THOMAS G | Director | Buy | 10K | $0.65 | $7K | 50K |
| 2023-11-21 | WIGGANS THOMAS G | Director | Buy | 10K | $0.64 | $6K | 40K |
| 2023-11-20 | WIGGANS THOMAS G | Director | Buy | 10K | $0.63 | $6K | 30K |
| 2023-11-17 | WIGGANS THOMAS G | Director | Buy | 10K | $0.60 | $6K | 20K |
| 2023-11-16 | WIGGANS THOMAS G | Director | Buy | 10K | $0.60 | $6K | 10K |
| 2023-10-13 | Lis William | Director | Sell | 8K | $0.85 | $7K | 54K |
| 2023-10-12 | MARTELL RON | President, CEO & Director | Tax withholding | 88K | $0.85 | $74K | 331K |
| 2023-10-12 | Mahal Jeetinder Singh | Chief Operating Officer | Tax withholding | 37K | $0.85 | $32K | 250K |
| 2023-06-13 | Mahal Jeetinder Singh | See Remarks | Exercise or conversion | 9K | $0.71 | $6K | 296K |
| 2023-06-13 | Mahal Jeetinder Singh | See Remarks | Sell | 9K | $1.66 | $15K | 287K |
| 2023-04-14 | French Anna Louise | Director | Sell | 7K | $1.48 | $10K | 24K |
| 2023-04-13 | Lis William | Director | Sell | 9K | $1.44 | $12K | 61K |
| 2023-04-13 | EMSTER KURT VON | Director | Sell | 9K | $1.49 | $14K | 21K |
| 2023-04-12 | Mahal Jeetinder Singh | See Remarks | Tax withholding | 37K | $1.46 | $54K | 287K |
| 2023-04-12 | MARTELL RON | President, CEO and Director | Tax withholding | 88K | $1.46 | $128K | 419K |
| 2023-01-27 | Qiming U.S. Healthcare GP II, LLC | TenPercentOwner | Buy | 2.7M | $1.50 | $4.0M | 8.5M |
| 2023-01-27 | TC Group, LLC | TenPercentOwner | Buy | 3.1M | $1.50 | $4.7M | 8.8M |
| 2023-01-25 | ROCHE FINANCE LTD | TenPercentOwner | Sell | 75K | $1.89 | $142K | 4.5M |
| 2022-10-12 | French Anna Louise | Director | Grant | 31K | $0.00 | $0 | 31K |
| 2022-10-12 | Lis William | Director | Grant | 30K | $0.00 | $0 | 70K |
| 2022-10-12 | Nolet Chris | Director | Grant | 33K | $0.00 | $0 | 33K |
| 2022-10-12 | Mahal Jeetinder Singh | See Remarks | Grant | 215K | $0.00 | $0 | 324K |
| 2022-10-12 | Shizuru Judith Anne | Director | Grant | 30K | $0.00 | $0 | 1.2M |
| 2022-10-12 | EMSTER KURT VON | Director | Grant | 30K | $0.00 | $0 | 30K |
| 2022-10-12 | Klein Lawrence Otto | Director | Grant | 25K | $0.00 | $0 | 25K |
| 2022-10-12 | MARTELL RON | President, CEO and Director | Grant | 506K | $0.00 | $0 | 506K |
| 2022-06-27 | Lis William | Director | Sell | 25K | $2.08 | $51K | 40K |
| 2022-06-24 | Lis William | Director | Sell | 25K | $2.02 | $50K | 65K |
| 2022-03-21 | Lis William | See Remarks | Grant | 90K | $0.00 | $0 | 90K |
| 2021-09-24 | Amplitude Healthcare Holdings LLC | TenPercentOwner | Exercise or conversion | 2.3M | price not stated in the filing | not stated | 2.3M |
| 2021-09-24 | VENKATARAMAN BALAJI | Other | Exercise or conversion | 2.3M | price not stated in the filing | not stated | 2.3M |
| 2021-09-24 | HOFFEN HOWARD I | Other | Exercise or conversion | 2.3M | price not stated in the filing | not stated | 2.3M |
| 2021-09-24 | Clifford Kenneth F | Other | Exercise or conversion | 2.3M | price not stated in the filing | not stated | 2.3M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first, 50 of 51 shown. JSON8 holders report 5% or more of JSPR in their latest filing, all on Schedule 13G (passive). The largest reported stake is Morgan Adam at 9.9% of the class (3,363,347 shares), filed 2026-08-17 for an event on 2026-08-17.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-17 | 13G | Morgan Adamindividual | 3.4M | 9.9% | 2026-08-17 |
| 2026-08-17 | 13G | Velan Capital Investment Management LPpartnership | 3.4M | 9.9% | 2026-08-17 |
| 2026-08-17 | 13G | Velan Capital Management LLCother entity | 3.4M | 9.9% | 2026-08-17 |
| 2026-08-17 | 13G | VENKATARAMAN BALAJIindividual | 3.4M | 9.9% | 2026-08-17 |
| 2026-08-17 | 13G | Velan Capital Master Fund LPpartnership | 3.0M | 8.9% | 2026-08-17 |
| 2026-08-17 | 13G | Velan Capital Holdings LLCother entity | 3.0M | 8.9% | 2026-08-17 |
| 2026-08-17 | 13G | Avego Healthcare Capital Holdings, LLCother entity | 244K | 0.7% | 2026-08-17 |
| 2026-08-17 | 13G | Avego Management LLCother entity | 244K | 0.7% | 2026-08-17 |
| 2026-08-17 | 13G | Avego Healthcare Capital, L.P.partnership | 244K | 0.7% | 2026-08-17 |
| 2026-08-17 | 13G | Velan Horizon GP LLCother entity | 82K | 0.2% | 2026-08-17 |
| 2026-08-17 | 13G | Velan Horizon Fund LPpartnership | 82K | 0.2% | 2026-08-17 |
| 2026-08-17 | 13G | Kapoor Vishalindividual | 35K | 0.1% | 2026-08-17 |
| 2026-07-10 | 13G/Ano. 1 | Millennium Group Management LLCother entity | 487K | 1.7% | 2026-06-30 |
| 2026-07-10 | 13G/Ano. 1 | Israel A. Englanderindividual | 487K | 1.7% | 2026-06-30 |
| 2026-07-10 | 13G/Ano. 1 | Millennium Management LLCother entity | 487K | 1.7% | 2026-06-30 |
| 2026-07-10 | 13G/Ano. 1 | Integrated Core Strategies (US) LLCother entity | 486K | 1.7% | 2026-06-30 |
| 2026-05-12 | 13G/Ano. 1 | Morgan Stanleyparent holding company, corporation | 1.3M | 4.8% | 2026-03-31 |
| 2026-05-12 | 13G/Ano. 1 | Morgan Stanley Capital Services LLCbroker-dealer, corporation | 1.3M | 4.6% | 2026-03-31 |
| 2026-05-08 | 13G/Ano. 4 | Guy Levyindividual | 276K | 1.0% | 2026-03-31 |
| 2026-05-08 | 13G/Ano. 4 | Soleus GP, LLCother entity | 276K | 1.0% | 2026-03-31 |
| 2026-05-08 | 13G/Ano. 4 | Soleus Capital Management, L.P.partnership | 276K | 1.0% | 2026-03-31 |
| 2026-05-08 | 13G/Ano. 4 | Soleus PE GP III, LLCother entity | 157K | 0.6% | 2026-03-31 |
| 2026-05-08 | 13G/Ano. 4 | Soleus Private Equity Fund III, L.P.partnership | 157K | 0.6% | 2026-03-31 |
| 2026-05-08 | 13G/Ano. 4 | Soleus Private Equity GP III, LLCother entity | 157K | 0.6% | 2026-03-31 |
| 2026-05-08 | 13G/Ano. 4 | Soleus Capital, LLCother entity | 119K | 0.4% | 2026-03-31 |
| 2026-05-08 | 13G/Ano. 4 | Soleus Capital Master Fund, L.P.non-US institution | 119K | 0.4% | 2026-03-31 |
| 2026-05-08 | 13G/Ano. 4 | Soleus Capital Group, LLCother entity | 119K | 0.4% | 2026-03-31 |
| 2026-05-08 | 13G/Ano. 1 | THE GOLDMAN SACHS GROUP, INC.parent holding company, corporation | 129K | 0.5% | 2026-03-31 |
| 2026-05-08 | 13G/Ano. 1 | GOLDMAN SACHS & CO. LLCbroker-dealer, other entity, investment adviser | 129K | 0.5% | 2026-03-31 |
| 2026-02-18 | 13D/Ano. 4 | Abingworth Bioventures VII LPpartnership | 1.1M | 3.8% | 2026-02-18 |
| 2026-02-18 | 13D/Ano. 4 | The Carlyle Group Inc.corporation | 1.1M | 3.8% | 2026-02-18 |
| 2026-02-18 | 13D/Ano. 4 | Carlyle Holdings I GP Inc.corporation | 1.1M | 3.8% | 2026-02-18 |
| 2026-02-18 | 13D/Ano. 4 | Carlyle Holdings I GP Sub L.L.C.other entity | 1.1M | 3.8% | 2026-02-18 |
| 2026-02-18 | 13D/Ano. 4 | Carlyle Holdings I L.P.partnership | 1.1M | 3.8% | 2026-02-18 |
| 2026-02-18 | 13D/Ano. 4 | CG Subsidiary Holdings L.L.C.other entity | 1.1M | 3.8% | 2026-02-18 |
| 2026-02-18 | 13D/Ano. 4 | TC Group, L.L.C.other entity | 1.1M | 3.8% | 2026-02-18 |
| 2026-02-18 | 13D/Ano. 4 | Carlyle Investment Management L.L.C.other entity | 1.1M | 3.8% | 2026-02-18 |
| 2026-02-18 | 13D/Ano. 4 | Carlyle Genesis UK LLCother entity | 1.1M | 3.8% | 2026-02-18 |
| 2026-02-18 | 13D/Ano. 4 | Abingworth LLPpartnership | 1.1M | 3.8% | 2026-02-18 |
| 2026-01-26 | 13G/Ano. 1 | Anders Hoveindividual | 1.5M | 5.3% | 2026-01-23 |
| 2026-01-26 | 13G/Ano. 1 | ACORN BIOVENTURES 2, L.P.partnership | 862K | 3.1% | 2026-01-23 |
| 2026-01-26 | 13G/Ano. 1 | Acorn Capital Advisors GP 2, LLCother entity | 862K | 3.1% | 2026-01-23 |
| 2026-01-26 | 13G/Ano. 1 | ACORN BIOVENTURES, L.P.partnership | 624K | 2.2% | 2026-01-23 |
| 2026-01-26 | 13G/Ano. 1 | ACORN CAPITAL ADVISORS GP, LLCother entity | 624K | 2.2% | 2026-01-23 |
| 2025-11-14 | 13G | T. Rowe Price Investment Management, Inc.investment adviser | 2.1M | 7.1% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | Mark McDadeindividual | 929K | 3.3% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | Qiming U.S. Healthcare Fund II, L.P.partnership | 929K | 3.3% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | Qiming U.S. Healthcare GP II, LLCother entity | 929K | 3.3% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | GARY E RIESCHELindividual | 929K | 3.3% | 2025-09-30 |
| 2025-11-12 | 13G/Ano. 1 | Mark Kingdonparent holding company, individual | 1.3M | 4.7% | 2025-09-30 |
13F holders
Tracked managers holding JSPR at their latest 13F. JSON2 of the 30 tracked managers held JSPR at their latest 13F, $305K in total at quarter-end prices. Millennium Management is the largest at $205K (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 1 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Millennium Management | 2026-06-30 | 487K | $205K | 0.00% | -1.1M |
| Renaissance Technologies | 2026-06-30 | 238K | $100K | 0.00% | +60K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Jasper Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Jasper Therapeutics (JSPR), SEC CIK 1788028, listed on Nasdaq. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-23.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-30.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-17.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-14.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2025-09-22.JSON and CSV
- Company record
- EDGAR filing index for CIK 1788028Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other company pages
- MLMMartin Marietta Materials
- MMM3M
- MNSTMonster Beverage
- MOAltria Group
- MODModine Manufacturing
- MOSMosaic
- MPMP Materials
- MPCMarathon Petroleum
- MPWRMonolithic Power Systems
- MRKMerck
- MRNAModerna
- MRSHMarsh & McLennan Companies
- MRVLMarvell Technology
- MSMorgan Stanley
- MSCIMSCI
- MSFTMicrosoft
- MSIMotorola Solutions
- MSTRStrategy
- MTBM&T Bank
- MTCHMatch Group
- MTDMettler-Toledo International
- MTNVail Resorts
- MTSIMACOM Technology Solutions Holdings
- MTZMasTec
Datasets
Frequently Asked Questions
How much of JSPR is sold short?
6,218,239 shares were held short at the 2026-09-30 settlement, 16.3 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is JSPR's daily short volume?
On 2026-10-23, 35,785 of the 91,092 JSPR shares reported to FINRA were sold short, 39.3% of the day's reported volume. Short volume is a flow for one day, not a position.
Does JSPR have fails to deliver?
The SEC's latest file shows 94,235 JSPR shares failed to deliver at settlement 2026-09-30. Fails are reported per settlement date and published twice a month with a lag.
Are JSPR insiders buying or selling?
No open-market insider trades were reported for JSPR in the last 90 days. The most recent filings are listed below. Latest filing: WIGGANS THOMAS G (Director) on 2025-09-22.
Who owns 5% or more of JSPR?
8 holders report 5% or more of JSPR in their latest filing, all on Schedule 13G (passive). The largest reported stake is Morgan Adam at 9.9% of the class (3,363,347 shares), filed 2026-08-17 for an event on 2026-08-17.
Which tracked 13F managers own JSPR?
2 of the 30 tracked 13F managers held JSPR shares at their latest filing, $305K in all. The largest: Izzy Englander's Millennium Management (487K shares, $205K), Renaissance Technologies (238K shares, $100K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.